FGFR amplification has been reported in various cancers, including FGFR1 amplification in estrogen receptor‐positive breast cancer and squamous cell lung cancer, and FGFR2 amplification in triple negative breast cancer and gastric cancer (Wang et al., 2014). Here, FGFR1 is linked to triple-negative breast carcinoma.